Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hypothetical protein, conserved | 0.0875 | 1 | 0.5 |
Onchocerca volvulus | 0.0752 | 0.7411 | 0.7411 | |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0875 | 1 | 0.5 |
Brugia malayi | Kringle domain containing protein | 0.0875 | 1 | 1 |
Onchocerca volvulus | 0.0752 | 0.7411 | 0.7411 | |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0875 | 1 | 0.5 |
Onchocerca volvulus | 0.0752 | 0.7411 | 0.7411 | |
Loa Loa (eye worm) | hypothetical protein | 0.0752 | 0.7411 | 0.7411 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0875 | 1 | 0.5 |
Onchocerca volvulus | 0.0875 | 1 | 1 | |
Brugia malayi | SEA domain containing protein | 0.0752 | 0.7411 | 0.7411 |
Toxoplasma gondii | kringle domain-containing protein | 0.0875 | 1 | 0.5 |
Onchocerca volvulus | 0.0752 | 0.7411 | 0.7411 | |
Loa Loa (eye worm) | hypothetical protein | 0.0875 | 1 | 1 |
Brugia malayi | Muscle positioning protein 4 | 0.0852 | 0.9519 | 0.9519 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0875 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0875 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0484 | 0.1786 | 0.1786 |
Echinococcus granulosus | tissue type plasminogen activator | 0.0875 | 1 | 0.5 |
Onchocerca volvulus | 0.0852 | 0.9519 | 0.9519 | |
Loa Loa (eye worm) | hypothetical protein | 0.0852 | 0.9519 | 0.9519 |
Schistosoma mansoni | hypothetical protein | 0.0752 | 0.7411 | 0.6881 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.0875 | 1 | 0.5 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0752 | 0.7411 | 0.7411 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.004 uM | Cytotoxicity against human DU145 cells after 2 days | ChEMBL. | 21419530 |
IC50 (functional) | = 1.32 uM | Cytotoxicity against human MDA-MB-231 cells after 2 days | ChEMBL. | 21419530 |
IC50 (functional) | = 3.41 uM | Cytotoxicity against human HL60 cells after 2 days | ChEMBL. | 21419530 |
IC50 (functional) | = 4.64 uM | Cytotoxicity against human HeLa cells after 2 days | ChEMBL. | 21419530 |
IC50 (functional) | = 14.8 uM | Cytotoxicity against human HCT116 cells after 2 days | ChEMBL. | 21419530 |
Inhibition (binding) | = 0 % | Inhibition of human recombinant topoisomerase 1-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins using ethidium bromide staining by transillumination analysis | ChEMBL. | 21419530 |
Inhibition (binding) | = 15.8 % | Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 10 uM after 30 mins using ethidium bromide staining by transillumination analysis | ChEMBL. | 21419530 |
Inhibition (binding) | = 22.24 % | Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins using ethidium bromide staining by transillumination analysis | ChEMBL. | 21419530 |
Inhibition (binding) | = 45.33 % | Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins using ethidium bromide staining by transillumination analysis | ChEMBL. | 21419530 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 21419530 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.